Update on pediatric atopic dermatitis.

Recent studies have led to new insights into atopic dermatitis (AD) pathogenesis and epidemiology as well as its impact on the quality of life of affected children and adolescents. In addition, there are several novel topical and systemic agents recently approved and in late-stage clinical development programs. Epidemiologic insights include relative prevalence rates in different countries and studies of subsets of pediatric patients with different disease longevity and persistence. Studies on quality of life have shown tremendous impact on sleep, not only in affected individuals but in their parents/guardians. The impact of bathing regimens is discussed. Newer topical therapies are reviewed, including topical crisaborole, with a new indication for infants as young as 3 months of age. Topical Janus kinase (JAK) inhibitors are being developed, with some studies including adolescents and children. Other novel therapies include the topical aryl hydrocarbon receptor agonist tapinarof and oral JAK inhibitors; adolescents are being included in the initial clinical trials for several of these therapies. Dupilumab, the first biologic agent approved for AD, has now been well studied in patients aged 6 years and older, with expanded indication down to 6 years of age.

[1]  K. Papp,et al.  Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies. , 2020, Journal of the American Academy of Dermatology.

[2]  C. Flohr,et al.  Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial , 2020, The Lancet.

[3]  J. Werth,et al.  Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1) , 2020, American Journal of Clinical Dermatology.

[4]  Sohita Dhillon.  Delgocitinib: First Approval , 2020, Drugs.

[5]  Dr Ivan D Cardona,et al.  Frequent Versus Infrequent Bathing in Pediatric Atopic Dermatitis: A Randomized Clinical Trial. , 2019, The journal of allergy and clinical immunology. In practice.

[6]  John D. Davis,et al.  Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis , 2019, JAMA dermatology.

[7]  N. Stahl,et al.  Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension , 2019, The British journal of dermatology.

[8]  H. Nakagawa,et al.  Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. , 2019, The Journal of allergy and clinical immunology.

[9]  J. Silverberg,et al.  The prevalence and persistence of atopic dermatitis in urban United States children. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[10]  C. McCulloch,et al.  Assessment of Sleep Disturbances and Exhaustion in Mothers of Children With Atopic Dermatitis , 2019, JAMA dermatology.

[11]  M. Chren,et al.  Association of Atopic Dermatitis With Sleep Quality in Children , 2019, Pediatrics.

[12]  A. Paller,et al.  A phase 2, randomized dose‐finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis , 2019, Journal of the American Academy of Dermatology.

[13]  J. C. Jaworski,et al.  Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders , 2018, American Journal of Clinical Dermatology.

[14]  A. Mitchell.  Bidirectional relationships between psychological health and dermatological conditions in children , 2018, Psychology research and behavior management.

[15]  J. Silverberg,et al.  Association between childhood atopic dermatitis and cutaneous, extracutaneous and systemic infections , 2018, The British journal of dermatology.

[16]  David M. Evans,et al.  Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts , 2017, Pediatrics.

[17]  L. Skov,et al.  Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis , 2017, Journal of the American Academy of Dermatology.

[18]  J. Silverberg.  Public Health Burden and Epidemiology of Atopic Dermatitis. , 2017, Dermatologic clinics.

[19]  C. Gieger,et al.  Association of Atopic Dermatitis with Cardiovascular Risk Factors and Diseases. , 2017, The Journal of investigative dermatology.

[20]  Kathy A Fraser.  American Academy of Dermatology Annual Meeting , 2017, American Journal of Clinical Dermatology.

[21]  E. Kempe,et al.  Bathing frequency recommendations for pediatric atopic dermatitis: are we adding to parental frustration? , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[22]  J. Silverberg,et al.  Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization , 2013, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[23]  E. Simpson,et al.  Mental health comorbidity in patients with atopic dermatitis. , 2013, The Journal of allergy and clinical immunology.

[24]  L. Eichenfield,et al.  Quantitative Assessment of Combination Bathing and Moisturizing Regimens on Skin Hydration in Atopic Dermatitis , 2009, Pediatric dermatology.

[25]  Erika Sevetson,et al.  The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. , 2017, The Journal of investigative dermatology.

[26]  M. Šitum,et al.  Quality of Life in Families with Children with Atopic Dermatitis , 2016, Pediatric dermatology.